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3rd-line therapy, analyzed from a third-party US payer perspective. Efficacy pa-
rameters included placebo-adjusted absolute weekly rates of remission and re-
sponse, taken from MDD treatment trials. Continuation, add-on, switch, and dis-
continuation rates, and inpatient and outpatient costs, were derived from the
PharMetrics database (Jan 2003–Mar 2008). Pharmacy costs were based on Whole-
sale Acquisition Costs. A budget impact model determined annual health care
costs of adding adjunct QTP XR to a formulary assuming a population of 185,000
patients,with 1.2%being treated forMDD.RESULTS:Adjunct QTPXR (300mg/d, but
not 150 mg/d) reduced total costs per remitting patient: $1998 versus adjunct ARP
when used in 2nd-line therapy ($17,168 vs $19,166) and $2608 in 3rd-line therapy
($22,051 vs $24,659). Themain drivers ofmodel outcomeswere pharmacy costs and
clinical efficacy. Probabilistic sensitivity analyses suggest model outcomes were
generally stable to varying assumptions. Increasing QTP XR use from 3.6% to 4.6%,
assuming a reduction in the use of other MDD treatments, increased overall health
care costs by 0.5% ($10,851,702–$10,909,591), with pharmacy costs rising by 2.3%
($3,006,169–$3,076,594). CONCLUSIONS: QTP XR (300 mg/d) as adjunct therapy, in
patients with MDD who previously have had an inadequate response to 1st- or
2nd-line therapy,was cost-effective in achieving remission comparedwith adjunct
ARP (15mg/d). Increasing QTP XR use as 2nd- or 3rd-line therapy had a limited and
well-defined budget impact. Supported by AstraZeneca Pharmaceuticals LP, Wil-
mington, Delaware.
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OBJECTIVES: In 2009, 8,211 hospitalizations for major depressive disorder (MDD)
occurred in Brazilian public hospitals, withmean duration of 20.5 days and average
cost of 770BRL. To inform decision-makers about more efficient therapeutic strat-
egies, this study aimed to compare costs of desvenlafaxine, escitalopram and du-
loxetine in the treatment of MDD inpatients from Brazilian public hospital
perspective.METHODS: A decision tree model was built to assess costs of desven-
lafaxine 50 mg/d, escitalopram 10 mg/d and duloxetine 60 mg/d to treat inpatients
admitted due to MDD. Four health states were considered: remission, dose escala-
tion due to lack of response, switching to another antidepressant after discontin-
uation caused by adverse event or failure, and treatment failure. This assessment
assumes similar efficacy among alternatives due to lack of head-to-head clinical
trials. Cost estimation assumed an 8-week time horizon. Relative risk of dropout
versus placebo was obtained through systematic review. Only direct medical costs
were considered and the cost components were drug acquisition costs and daily
room charges. One-way sensitivity analyses were performed using drug prices,
proportion of duloxetine patients requiring drug titration, and daily room charges
(20%) as key variables. RESULTS: Desvenlafaxine avoided 12% of estimated drop-
outs compared to competing alternatives. The estimated treatment costs were
1,955BRL, 2,213BRL and 2,476BRL per patient treated with desvenlafaxine, escita-
lopram and duloxetine, respectively. Therefore, desvenlafaxine exhibited savings
of257BRL and520BRL versus escitalopram and duloxetine, respectively.Within
sensitivity analyses, the lower saving was observed when duloxetine titration was
set as 0% (94BRL versus escitalopram) and the higher when a20% variation was
applied to daily room charges (-580BRL versus duloxetine). CONCLUSIONS: Des-
venlafaxine would be a cost-saving strategy compared to escitalopram and dulox-
etine in the treatment of patients admitted to the hospital due to MDD, given its
lower price and lower dropout rates as a consequence of side effects.
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OBJECTIVES: Depression symptoms in medically ill patients are known to ad-
versely impact treatment compliance, healthcare costs and outcomes. Thus, this
study aims to compare costs of desvenlafaxine, escitalopram and duloxetine in
medically ill inpatients with associated major depressive disorder (MDD) from the
Brazilian public general hospital perspective. METHODS: A decision-tree model
was built to assess costs of desvenlafaxine 50 mg/d, escitalopram 10 mg/d and
duloxetine 60 mg/d to treat patients with MDD in Brazilian public hospitals. Four
health states were considered: remission, dose escalation due to lack of response,
switching to another antidepressant after discontinuation caused by adverse
event, and treatment failure. Assessment assumed similar efficacy among alter-
natives due to lack of head-to-head clinical trials. Cost estimation assumed an
8-week time horizon. Relative risk of dropouts compared to placebo was obtained
through literature systematic review. Since the model assumed that hospitaliza-
tion are not due to MDD, only drug acquisition costs were considered in the base
case. Unit costs were: 3.09BRL, 4.04BRL and 6.91BRL for desvenlafaxine, escitalo-
pram and duloxetine, respectively. Official prices were obtained from 2010 CMED/
ANVISA list. One-way sensitivity analyses were performed using drug prices and
proportion of duloxetine patients requiring drug titration as key variables.
RESULTS: Desvenlafaxine avoided 12% of estimated dropouts compared to com-
peting alternatives. The estimated treatment costs were 144BRL, 250BRL and
364BRL per patient treated with desvenlafaxine, escitalopram and duloxetine, re-
spectively. Therefore, desvenlafaxine exhibited savings of 106BRL and 220BRL
versus escitalopram and duloxetine, respectively. Within the sensitivity analyses,
the lower and higher savings were observed when Brazilian public procurement
priceswere adopted (82BRL versus escitalopramand216BRL versus duloxetine).
CONCLUSIONS: Desvenlafaxine would be a cost-saving strategy compared to esci-
talopram and duloxetine in medically ill inpatients treated for MDD, due its lower
price and lower dropout rates as a consequence of side effects.
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ECONOMIC IMPACT OF CYP450 PHARMACOGENETIC TESTING ON DEPRESSION
TREATMENT
Syeda SS, Wu WK
St. John’s University, Jamaica, NY, USA
OBJECTIVES: CYP450 enzyme activities have been associated with inter-individual
variability affecting efficacy and tolerability among non-psychotic major depres-
sive disorder (MDD) patients. Pre-prescription pharmacogenetic testing helps to
identify patients with increased risk for adverse reactions, lack of efficacy and
increased hospitalization costs. These test results could assist doctors to prescribe
alternative therapy or optimum doses. Present study is to estimate the cost effec-
tiveness of pre-prescription pharmacogenetic testing to assess the CYP450 enzyme
activity for the treatment of depression using selective serotonin reuptake inhibi-
tors (SSRIs).METHODS:Markov model was developed from societal perspective to
identify cost and quality adjusted lifemonths (QALM) gained for carrying out phar-
macogenetic testing compared to no test strategy. A systematic search of the liter-
ature was carried out to identify published evidence for associations between ad-
verse events, dropout rates and the three phenotypic groups: ultrafast
metabolizers, poor metabolizers and intermediate metabolizers. Potentially rele-
vant papers were used to derive the transitional probabilities, costs and sensitivity
as well as specificity of CYP450 enzyme testing technique. Multiple one-way sen-
sitivity analyses were performed to find the robustness of the model. RESULTS:
Projected outcomes associated with pre-prescription CYP450 testing strategy for a
patient with MDD was $4367/6.5 compared to $5634/6.4 QALM in no test strategy.
The testing strategywas found to be dominant between the above two options. The
model was found to be sensitive to utility values, cost of adverse events follow up,
percentage of ADRdropouts and remission rates.CONCLUSIONS:The study results
indicate that CYP450 genotype-guided SSRI treatment for depression is potentially
cost saving and leads to improved quality of life in patients. Yet the model is not
robust with respect to selected clinical and economic variables. Further studies
should be pursued to confirm the value of genotype-guided therapy before broadly
applying in the regular clinical practice
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FUNCTION
Ghushchyan VH, Campbell JD, Libby AM
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OBJECTIVES: Human capital theory posits that education, experience and health
are the main contributors to the value of labor, measured as individual wage or
earnings. We quantified the effects of general physical and mental health on an-
nual wage and possible inefficiencies in reaching the wage frontier for a U.S. rep-
resentative population.METHODS:Weutilized theMedical Expenditure Panel Sur-
vey for 2000-2007 for individual economic and health measures and population
estimates. General health wasmeasured using validated instruments (SF-12 phys-
ical and mental scores). Annual wage was expressed in 2009 US dollars. Stochastic
frontier regression was used to estimate the impact of physical and mental health
on annual wage. The model estimated wage function and individual level ineffi-
ciency. Specifically, annual wage wasmodeled as a function of years of experience
and educational attainment, plus physical and mental health, controlling for gen-
der, race/ethnicity, and region. Sensitivity analyseswere conducted to examine the
impact of varying assumptions on the results. RESULTS: A one percent increase in
physical health status resulted in 0.32% (0.27% - 0.36%) increase of annualwage and
one percent increase in mental health status resulted in 0.13% (0.09% - 0.16%)
increase of annual wage. The summative elasticity of these two health factors is
greater than the elasticity of experience: 0.38% (0.36% - 0.39%). In addition better
physical and mental health are associated with higher productivity and smaller
variations of inefficacy and stochastic error variance. CONCLUSIONS: General
physical and mental health make significant contributions to human capital as
reflected in wages in the U.S., as well as in expected productivity gains. Deficits in
human health are estimated to leave potential productivity gains unrealized. The
relativemagnitude of the health effect compared to the experience effect supports
larger investments in access to health care.
Mental Health – Patient-Reported Outcomes & Preference-Based Studies
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MEASURES OF MEDICATION ADHERENCE IN ORAL VERSUS LONG-ACTING
RISPERIDONE IN TEXAS MEDICAID PATIENTS WITH SCHIZOPHRENIA
Kim DN, Park H, Rascati KL
University of Texas at Austin, Austin, TX, USA
OBJECTIVES: Medication adherence has been shown to be an important factor in
preventing schizophrenia-related relapses, and long-acting injectable risperidone
has been shown to be effective in improving medication adherence. The objective
of this study was to determine the medication adherence rates of schizophrenic
patients treatedwith either oral risperidone only (oral cohort) or long-acting inject-
able risperidone/ oral risperidone (injectable cohort).METHODS: Texas Medic-
aid prescription claims data (January 2006 to December 2008) were analyzed for
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patients with ICD-9CM codes for schizophrenia (295.xx). Records were assessed for
a period of 18 months (6-month pre-index period with no antipsychotics plus 12-
month post-index period). A medication possession ratio (MPR) of  80% or a pro-
portion of days covered (PDC) of 80%was considered adherent. RESULTS: A total
of 1,470 patients met inclusion criteria; 31% (n462) had an MPR  80%. Based on
MPR, 30% (405/1338) in the oral cohort and 43% (57/132) in the injectable cohort
were adherent. Logistic regression analyses adjusting for demographic covariates
(age, gender, race) showed that patients in the injectable cohort were about 77%
more likely to be adherent based on MPR (OR1.77, 95% CI1.22-2.56, p0.05)
compared to the oral cohort. Of the demographic covariates, race (Blacks  less
adherent; p0.001) was the only significant covariate. Similarly, increased adher-
ence in the injectable cohort (OR1.81, 95% CI1.24-2.63, p0.05) was also found
using PDC, where race (Blacks less adherent; p0.001) and gender (women less
adherent; p0.05) were significant. CONCLUSIONS: Overall, less than one-third of
all patients were adherent (MPR  80%) one year after their index date. Patients
taking long-acting injectable risperidone had higher rates of adherence compared
to patients taking oral risperidone alone. In addition, this findingwas confirmed by
PDC, which has been shown to be a more conservative calculation of adherence in
patients with schizophrenia.
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HYPERLIPIDEMIA, AND HYPERTENSION MEDICATIONS AND ASSOCIATED
HEALTH SERVICE UTILIZATION
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OBJECTIVES: To examine the association of antipsychotic adherence with adher-
ence to medications for diabetes, hyperlipidemia, and hypertension and with
healthcare utilization.METHODS:Medstat Medicaid claims data were used to gen-
erate cohorts of patients with schizophrenia newly initiating a second generation
antipsychotic and using medications for diabetes, hypertension, and hyperlipid-
emia. Quarterly (Q) adherence measurements were calculated for each patient to
capture initiation (Q1), continuation (Q2-Q4), andmaintenance (Q5-Q8) periods via
the proportion of days covered (PDC)  80%. Generalized estimating equations
examined the association of initiation period antipsychotic adherencewith comor-
bid medication adherence and health service utilization during the continuation
phase. Similarly, continuation phase antipsychotic adherence was used to predict
parallel maintenance phase outcomes. RESULTS: Patients adherent to antipsy-
chotic treatment during initiation (Q1) were more adherent to medications for
diabetes [Odds Ratio (OR) 1.77; 95% CI(0.95, 3.29)], hypertension [1.36, (0.91, 2.04)],
and hyperlipidemia [2.24, (1.02, 4.90)] during the continuation phase. Similarly,
continuation phase antipsychotic adherence was associated with higher adher-
ence to medications for diabetes [4.99, (2.85, 8.71)], hypertension [7.51, (5.07,
11.12)], and hyperlipidemia [5.68, (2.71, 11.92)] during the maintenance phase.
Higher antipsychotic adherence during the continuation phase also was asso-
ciated with more frequent outpatient visits [Incident Rate Ratio  1.53 (1.21,
1.94), 1.57 (1.35, 1.82), 1.63 (1.28, 2.07)], less frequent inpatient admission [OR 
0.73 (0.43, 1.26), 0.70 (0.49, 1.00), 0.87 (0.49, 1.54)] and less frequent emergency
department use [OR  0.68 (0.42, 1.10), 0.58 (0.47, 0.78), 0.76 (0.47, 1.25)] during
the maintenance phase among patients with diabetes, hypertension, and hy-
perlipidemia respectively. CONCLUSIONS: Antipsychotic adherence was associ-
ated with better adherence to medications for chronic comorbid health conditions
as well as a trend toward lower inpatient and emergency department use over a 2
year period. These findings suggest potential benefits to antipsychotic adherence
beyond mental health management.
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THE RELATIONSHIP BETWEEN BUPRENORPHINE-MEDICATION ASSISTED
TREATMENT ADHERENCE AND HEALTH CARE COSTS AND SERVICE
UTILIZATION: AN ANALYSIS OF AETNA’S OPIOID DEPENDENT MEMBERS
Tkacz J1, Un H2, Leader Jr D2, Ruetsch C1
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OBJECTIVES: Buprenorphine-medication assisted treatment (B-MAT) is an effec-
tive treatment for OD, but is hypothesized to have the greatest impact on those
patients who are compliant. This analysis was conducted to compare economic
costs and benefits between B-MAT compliant and non-compliant OD members.
METHODS: A longitudinal, multivariate analysis was conducted using service use
claims data among a sample of Aetna members with full benefit coverage and at
least one diagnoses of OD during the 48monthmeasurement period (Q1 2006 to Q4
2009). Medication possession ratio (MPR) was calculated for the sample (n  725).
Memberswith anMPR .80were classified as compliant (n 324), with the balance
classified as non-compliant (n  401). Two six-month measurement periods were
constructed around the index date. RESULTS: After B-MAT induction, compared to
non-compliant B-MATmembers, compliantmembers increased their total number
of prescriptions filled by an average of 2.57 per member (P  0.007). However,
B-MAT compliant members showed decreases in inpatient hospital admissions
(0.62), inpatient hospital days (4.77), and emergency room visits (0.42; P’s
0.001). Concerning healthcare costs, compliant B-MAT members increased their
spend at the pharmacy compared to non-compliant B-MATmembers by $1,059 per
member (P  0.001), but decreased inpatient hospital costs ($9,623) and ER costs
($1,068; P’s  0.001). Overall, compliant B-MAT members spent a total of $14,448
less (P 0.001) per member over the first six months of treatment. CONCLUSIONS:
Though compliant B-MAT patients incur higher pharmacy and costs, they use
fewer expensive health care services in other areas, resulting in an overall positive
cost-benefit conclusion for B-MAT. Compliance with medication-assisted treat-
ment is essential for patient recovery, but given that less than half of the sample
had an MPR  .80, additional treatment ancillaries or disease management pro-
grams may be needed to increase patient compliance.
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OBJECTIVES:Bipolar Disorder (BP) is a condition inwhich adherence to therapy and
medication is vital to help patients avoid severe social and emotional problems.
Patient beliefs are one of many important factors that determine patient adher-
ence.We sought to systematically review the literature on the role of patient beliefs
about their BP, their medications, and their health care team, and the impact these
beliefs have on adherence to both medication and therapy.METHODS: A system-
atic literature review was performed using Medline, PubMed and PsychInfo. The
eligibility criteria for studies were as follows: studies published from January 1,
2000 through March 28, 2010; patient sample comprised BP patients only; adher-
ence to either medication or therapy was a primary study outcome; measures of
patient beliefs or belief system were reported. Titles and abstracts were screened
for potentially relevant studies. RESULTS: A total of 10 studies met our study in-
clusion criteria; study participants usually consisted of BP patients recruited from
outpatient clinics and similar sites. A wide variety of beliefs ranging from disease
denial, doubt ofmedication efficacy, fear of side effects, desire for alternative treat-
ment, and conflicting religious ideas all had a negative impact on adherence to
medication and therapy. A strong patient-provider relationship, belief that medi-
cation was necessary, and belief that benefits outweighed risks were identified as
beliefs that positively impacted patient adherence.CONCLUSIONS:Themajority of
primary literature on BP patient beliefs and adherence focuses mostly around the
patient-provider relationship, and concerns aboutmedication side effects. There is
a lack of studies that deal with other patient beliefs such as how they feel about
their diagnosis, their belief in medication efficacy, and how their spiritual beliefs
affect adherence. A better understanding of patient beliefs may help improve cli-
nicians’ counseling techniques, and help them to encourage greater adherence to
medication and therapy.
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CAN THE ILLNESS PERCEPTION QUESTIONNAIRE BE USED TO ASSESS MENTAL
HEALTH PRACTITIONERS’ PERSPECTIVES ON PATIENTS WITH
SCHIZOPHRENIA?
Fleming M, Martin CR
University of the West of Scotland, Ayr, UK
OBJECTIVES:The Illness PerceptionQuestionnaire (IPQ)was designed as ameasure
of illness perception and has been adapted on many occasions for use in distinct
domains. More recently modified versions of the IPQ have been used to determine
the illness perceptions of people with schizophrenia and their carer’s. The current
investigation examined the utility of a modified version of the IPQ to assess
changes in mental health practitioners’ illness perceptions about schizophrenia
after completing postgraduate training in psychosocial interventions. METHODS:
A total of 245 mental health practitioners completed a modified version of the IPQ
pre and post training in a psychosocial interventions postgraduate course. The
structure of the questionnaire was evaluated using confirmatory factor analysis
and the internal consistencies of sub-scaleswithin the instrumentwere examined.
RESULTS: Model fit indices revealed a poor fit to the data across all of the models
evaluated (CFI  0.51-0.80, RMSEA  0.12-0.20). Internal consistency analysis re-
vealed a number of sub-scales (0.53-0.78) in the instrument to also have poor psy-
chometric qualities. CONCLUSIONS: The suitability of the modified version of the
IPQ for evaluating the impact psychosocial intervention training on changes in
illness perceptions of schizophrenia in mental health practitioners is not sup-
ported based on psychometric criteria. The need to develop a valid and reliable
measure to assess the illness perceptions of health professionals have of patients
in their care remains a priority.
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A TIME-TRADE-OFF STUDY OF HEALTH-RELATED QUALITY OF LIFE
ADVANTAGE OF LONG-ACTING INJECTABLE ANTIPSYCHOTIC TREATMENT FOR
SCHIZOPHRENIA
Osborne RH1, Dalton A2, Hertel J3, Schrover R4, Kingsford Smith D5
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OBJECTIVES: This study was undertaken to estimate utility values for alternative
treatment intervals for long acting antipsychotic intramuscular injections for the
treatment of schizophrenia. METHODS: Vignettes were developed using the pub-
lished literature and an iterative consultation process with expert clinicians and
patient representative groups. Four vignettes were developed. The first was a vi-
gnette of relapsed/untreated schizophrenia. The other three vignettes presented a
standardised picture of well managed schizophrenia with variations in the inter-
vals between injections: once every 2weeks, 4-weeks and 3months. The time trade
off (TTO) approach was used to obtain utility values for the vignettes. As a societal
perspective was sought, a representative sample of individuals from across the
community (Sydney, Australia) was recruited. Ninety-eight people completed the
TTO interview. The vignettes were presented in random order to prevent possible
ordering effects. RESULTS: A clear pattern of increasing utility was observed with
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